3H-10000 / 3H Pharma - LARVOL DELTA

Preclinical development of 3H-10000, a novel vedotin antibody-drug conjugate for treatment of FGFR2b-expressing cancers (AACR 2026) - "More important is that there existed significant synergy in tumor growth inhibition and regression in SNU-16 CDX study, when 3H-10000 was combined with a FGFR2 selective small molecule inhibitor 3HP-2827, which would strongly support clinic trail exploration of the combined therapy strategy of FGFR2b-ADC and 3HP-2827 to overcome drug resistance and perform persistent therapeutic efficacy. The safety study demonstrated that 3H-10000 spared corneal toxicity in mice compared with Bemarituzumab...Overall, 3H-10000, the novel FGFR2b ADC, is a highly potent targeted therapy candidate against cancers.Overall, this study is the first to our knowledge where the combinational treatment of FGFR2b ADC and FGFR2 selective kinase inhibitor demonstrated synergic inhibition of tumor cell growth. These results strongly support advancing 3H-10000 into clinical evaluation in treatment of unnormal FGFR2 expressing solid tumors, and a phase I study has (CTR20254555) is ongoing."

ADC • Late-breaking abstract • Preclinical • Gastric Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • FGFR2

A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=170 | Recruiting | Sponsor: 3H Pharmaceuticals Co., Ltd.

First-in-human • New P1/2 trial • Gastric Cancer • Lung Cancer • Oncology • Solid Tumor